Andrew S. Lee

Andrew S. Lee

Auto-generated profile, based on publicly available information

Andrew S. Lee

School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2023 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
YYYi You
Yi You
YTYu Tian
Yu Tian
Zhaogang YangZhaogang Yang
Zhaogang Yang
JSJunfeng Shi
Junfeng Shi
KKKwang Joo Kwak
Kwang Joo Kwak
ALAndrew S. Lee
Andrew S. Lee

19 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
SDShiyan Dong
Shiyan Dong
XLXuan Liu
Xuan Liu
YBYe Bi
Ye Bi
YWYifan Wang
Yifan Wang
AAAbin Antony
Abin Antony
WJWen Jiang
Wen Jiang
The recent success of mRNA therapeutics against pathogenic infections has increased interest in their use for other human diseases including cancer. However, the precise delivery of the genetic cargo to cells and tissues of interest remains challenging. Here, we show an adaptive strategy that enables the docking of different targeting ligands onto the surface of mRNA-loaded small extracellular vesicles (sEVs). This is achieved by using a microfluidic electroporation approach in which a combination of nano- and milli-second pulses produces large amounts of IFN-γ mRNA-loaded sEVs with CD64 overexpressed on their surface. The CD64 molecule serves as an adaptor to dock targeting ligands, such as anti-CD71 and anti-programmed cell death-ligand 1 (PD-L1) antibodies. The resulting immunogenic sEVs (imsEV) preferentially target glioblastoma cells and generate potent antitumour activities in vivo, including against tumours intrinsically resistant to immunotherapy. Together, these results provide an adaptive approach to engineering mRNA-loaded sEVs with targeting functionality and pave the way for their adoption in cancer immunotherapy applications.

23 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
CCChi-Ling Chiang
Chi-Ling Chiang
YMYifan Ma
Yifan Ma
YHYa-Chin Hou
Ya-Chin Hou
JPJunjie Pan
Junjie Pan
SCSin-Yu Chen
Sin-Yu Chen
LLL. James Lee
L. James Lee
Pancreatic ductal adenocarcinoma (PDAC) tumours carry multiple gene mutations and respond poorly to treatments. There is currently an unmet need for drug carriers that can deliver multiple gene cargoes to target high solid tumour burden like PDAC. Here, we report a dual targeted extracellular vesicle (dtEV) carrying high loads of therapeutic RNA that effectively suppresses large PDAC tumours in mice. The EV surface contains a CD64 protein that has a tissue targeting peptide and a humanized monoclonal antibody. Cells sequentially transfected with plasmid DNAs encoding for the RNA and protein of interest by Transwell®-based asymmetric cell electroporation release abundant targeted EVs with high RNA loading. Together with a low dose chemotherapy drug, Gemcitabine, dtEVs suppress large orthotopic PANC-1 and patient derived xenograft tumours and metastasis in mice and extended animal survival. Our work presents a clinically accessible and scalable way to produce abundant EVs for delivering multiple gene cargoes to large solid tumours.

6 May 2026 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
YMYIFAN MA
YIFAN MA
SDShiyan Dong
Shiyan Dong
AWAnnette Wu
Annette Wu
SJSeong Dong Jeong
Seong Dong Jeong
ALAndrew S. Lee
Andrew S. Lee
BKBetty Y. S. Kim
Betty Y. S. Kim

11 June 2026 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
YTYu Tian
Yu Tian
YLYutong Liu
Yutong Liu
YTYuhao Tong
Yuhao Tong
KHKristin Huntoon
Kristin Huntoon
LYLiqun Yang
Liqun Yang
ALAndrew S. Lee
Andrew S. Lee

11 November 2025 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
YYYuting Yan
Yuting Yan
YYYi You
Yi You
SMShuhong Ma
Shuhong Ma
HYHui Yi
Hui Yi
GCGuangduo Chen
Guangduo Chen
ZCZhaoyang Chen
Zhaoyang Chen
Adeno‐associated virus (AAV)–mediated gene therapies face critical clinical limitations, including immune‐mediated neutralization by pre‐existing antibodies and dose‐dependent hepatotoxicity. Extracellular vesicle‐encapsulated AAVs (EV‐AAVs) offer a promising solution by shielding AAVs from antibody recognition, yet existing production methods remain inefficient and impractical for clinical application. Here, we developed a cellular nanoporation (CNP) platform that enables scalable, high‐yield generation of EV‐AAVs, achieving an approximately 11‐fold increase in production efficiency compared with conventional methods. In LDLR‐deficient murine models with pre‐existing neutralizing antibodies (1:200), EV‐AAV‐LDLR at half the standard AAV dose robustly restored hepatic LDL receptor expression and attenuated atherosclerosis progression. Notably, EV‐AAV exhibited superior immune evasion capabilities, maintaining 2.3‐fold higher hepatic transduction efficiency than conventional AAV upon secondary dosing due to antibody shielding. Importantly, EV‐AAV therapy markedly reduced hepatotoxicity, with serum AST/ALT levels comparable to saline‐treated controls, thereby overcoming a critical safety barrier of high‐dose AAV treatment. These results demonstrate CNP as a clinically translatable platform for scalable EV‐AAV manufacturing, enabling effective multi‐dose regimens while overcoming key immunological and toxicity barriers in liver‐directed gene therapy for familial hypercholesterolaemia.